Log In
Print this Print this

Infimab, biosimilar infliximab (BOW015)

  Manage Alerts
Collapse Summary General Information
Company Epirus Biopharmaceuticals Inc.
DescriptionBiosimilar of infliximab, a chimeric mAb against tumor necrosis factor (TNF) alpha
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentMarketed
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation
PartnerChemo Group;
Livzon Pharmaceutical Group Inc.;
Polpharma S.A.;
Sun Pharmaceutical Industries Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today